RECRUITINGINTERVENTIONAL
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
About This Trial
The proposed project will have two separate cohorts. The first will be to perform a more in-depth qualitative assessment of the barriers and facilitators for treatment compliance for non-muscle invasive bladder cancer. The second arm will be to create and test a BCG at home program. Participants in the second cohort will be enrolled in a conversational agent to measure patient symptoms and quality of life and improve self-efficacy.
Who May Be Eligible (Plain English)
Who May Qualify:
Inclusion criteria for patients in Cohort 1
- Age 18 years or older;
- completed intravesical treatment for non-muscle invasive bladder cancer within the past year Cohort 1 inclusion criteria for key stakeholders
- Age 18 years or older;
- experience with the delivery of BCG delivery for more than 2 years
Cohort 2 inclusion criteria
- Age 18 years or older;
- diagnosed with non-muscle invasive bladder cancer and prescribed BCG for initial therapy
Who Should NOT Join This Trial:
Cohort 1 exclusion criteria
• inability to provide willing to sign a consent form
Cohort 2 exclusion criteria
- inability to provide willing to sign a consent form
- inability to undergo catheterization (i.e. - history of urethral stricture)
- inability to receive BCG therapy (i.e. - previous reaction with BCG)
- no access to mobile phone
- inability to respond to written conversations in English
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
Inclusion criteria for patients in Cohort 1
* Age 18 years or older;
* completed intravesical treatment for non-muscle invasive bladder cancer within the past year Cohort 1 inclusion criteria for key stakeholders
* Age 18 years or older;
* experience with the delivery of BCG delivery for more than 2 years
Cohort 2 inclusion criteria
* Age 18 years or older;
* diagnosed with non-muscle invasive bladder cancer and prescribed BCG for initial therapy
Exclusion Criteria:
Cohort 1 exclusion criteria
• inability to provide informed consent
Cohort 2 exclusion criteria
* inability to provide informed consent
* inability to undergo catheterization (i.e. - history of urethral stricture)
* inability to receive BCG therapy (i.e. - previous reaction with BCG)
* no access to mobile phone
* inability to respond to written conversations in English
Treatments Being Tested
OTHER
BCG delivery at home
The BCG at home project will be a single-arm prospective pilot, to evaluate the feasibility, scalability and effectiveness of home treatment, and utilize the BB-Bot (chatbot) for PRO and adverse event measurement.
Locations (1)
Abramson Cancer Center
Philadelphia, Pennsylvania, United States